Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 4/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922843 | 0.91 | CHRM5 (0.43) | CHRM5P2RY12NPC1RAB9ACA12 | |
| SCHEMBL14228637 | 0.91 | CHRM5 (0.34) | CHRM5P2RY12NPC1RAB9ACA12 | |
| SCHEMBL9922866 | 0.85 | P2RY12 (0.37) | P2RY12CA12CA1CA2CA9 | |
| SCHEMBL9922874 | 0.85 | P2RY12 (0.34) | P2RY12NPC1RAB9ACA12CA1 | |
| SCHEMBL9922864 | 0.84 | P2RY12 (0.37) | P2RY12CA12CA1CA2CA9 | |
| SCHEMBL12161634 | 0.83 | P2RY12 (0.36) | P2RY12CA12CA1CA2CA9 | |
| SCHEMBL9922863 | 0.83 | P2RY12 (0.35) | P2RY12RAB9ACA12CA1CA2 | |
| SCHEMBL9922268 | 0.82 | P2RY12 (0.45) | CHRM5P2RY12NPC1RAB9AFBP1 | |
| SCHEMBL13633797 | 0.81 | P2RY12 (0.35) | P2RY12CA12CA1CA2CA9 | |
| SCHEMBL9922809 | 0.81 | P2RY12 (0.44) | CHRM5P2RY12NPC1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | CHRM5 4324/4885P2RY12 19/4885NPC1 3119/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | CHRM5 4317/4885P2RY12 18/4885NPC1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.